DUBLIN--(http://www.researchandmarkets.com/research/9rfhd6/global_epilepsy) has announced the addition of the "Global Epilepsy Epidemiology and Patient Flow Analysis - 2012" report to their offering.)--Research and Markets (
“Global Epilepsy Epidemiology and Patient Flow Analysis - 2012”
Fore Pharma announced the results of its Epilepsy patient population study in a new report Global Epilepsy Epidemiology and Patient Flow Analysis - 2012'. The report provides insights into Epilepsy epidemiology, Epilepsy diagnosed patients, and Epilepsy treatment rate for top seven pharmaceutical markets. The study measures key indicators such as prevalence of Epilepsy derived from epidemiological analysis, percentage of patients diagnosed with Epilepsy, and percentage of patients treated with Epilepsy therapy.
The study helps executives estimate Epilepsy market potential, assess unmet need, develop drug forecasting models, and build population-based health management frameworks. The information presented in this study is used to evaluate market opportunities, effectively identify target patient population, and align marketing decisions.
The report provides estimates and forecasts of Epilepsy prevalence, Epilepsy diagnosis rate, and Epilepsy treatment rate for the period 2012-2019. The information is presented by leading geographies including the US, Germany, France, Spain, Italy, UK, and Japan. The study design is based on collection and interpretation of data from registries, scientific journals and literatures, government databases and other secondary sources.
Key Features of the Report:
- Epilepsy: Disease Definition
- Epilepsy Patient Flow
- Epilepsy Prevalence
- Epilepsy Diagnosed Patients
- Epilepsy Treated Patients
For more information visit http://www.researchandmarkets.com/research/9rfhd6/global_epilepsy